Project Grant R21AG083663
Award Date
9/15/24
Completion Date
6/30/26
Dollars Obligated
$428K
Federal Agency
National Institute on Aging
Federal Grant Program
93.866
Assistance Type
Project Grant
Place of Performance
Columbia, MO 65211, USA
Similar Awards
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $426,250 to Wake Forest University Health Sciences to develop and evaluate a novel positron emission tomography (PET) radiotracer, [11C]TM-N1324, to measure levels of the G-protein coupled receptor GPR39 in rodent models and postmortem human brain tissues of Alzheimer's disease (AD). The project aims to establish the utility of this PET imaging approach for quantifying GPR39, which is implicated...
This federal Project Grant award from the National Institute on Aging (NIA), under the Aging Research program (CFDA 93.866), provides $1,247,875 to Yale University to characterize the properties and performance of the PET radiotracer [18F]3F4AP for detecting and quantifying demyelination and cerebral perfusion in subjects with Alzheimer's disease (AD), mild cognitive impairment (MCI), and cognitively normal individuals. The research aims to perform the first full pharmacokinetic evaluation of...
The National Institute on Aging (NIA) awarded a $1,783,700.00 Project Grant under the Aging Research program (CFDA 93.866) to the University of Illinois to develop novel blood-brain barrier permeable multimodal imaging agents for the diagnosis of neurodegenerative diseases, with a focus on Alzheimer's disease and related dementias. The 3-year grant aims to employ organic and inorganic chemical design principles to generate diagnostic agents capable of detecting protein aggregation,...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $782,495 to Emory University to develop a novel positron emission tomography (PET) ligand that can quantify poly(ADP-ribose) polymerase-1 (PARP1) expression in the living brain. PARP1 dysregulation has been implicated in Alzheimer's disease and other neurodegenerative disorders, but no successful PARP1 brain imaging agents have been demonstrated to date. The project aims to optimize a lead...
This Project Grant from the National Institutes of Health's National Institute on Aging, under the Aging Research program (CFDA 93.866), provides $2,969,644 to develop a novel positron emission tomography (PET) imaging probe targeting myeloperoxidase (MPO) activity for detecting neuroinflammation in neurodegenerative diseases. The Massachusetts General Hospital will design and screen potential PET agents for detecting MPO activity in the brain, characterize and validate candidate MPO PET...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $106,464 to Brandeis University to conduct research on the associations between monoamine neurotransmitter systems, tau pathology, and emotional memory in aging. The research will utilize positron emission tomography (PET) imaging techniques to measure monoamine synthesis capacity and tau pathology in the brain, and relate these measures to performance on an emotional memory task. The findings...
The University of Missouri System was awarded a $392,026 Project Grant from the National Institute on Aging (CFDA 93.866 - Aging Research) to develop an innovative approach for treating Alzheimer's disease (AD). The key product being delivered is a novel therapeutic intervention that aims to systematically and sustainably elevate nicotinamide adenine dinucleotide (NAD+) levels in the body to counteract NAD+ decline associated with AD progression. The project will utilize a helper-dependent...
The National Institute on Aging (NIA) awarded a $2,547,870 Cooperative Agreement (CFDA 93.866 - Aging Research) to Weill Medical College of Cornell University to develop a high-resolution, cost-effective, portable, and upright brain PET scanner for early diagnosis of Alzheimer's disease. The project aims to integrate an ultra-high resolution electromagnetic motion tracker with the PRISM-PET brain scanner to enable quantitative assessment of tau deposition in early mild cognitive impairment....
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $497,878 to Einsenca Inc. to conduct a first-in-human Phase 0 clinical study of the 18F-EH301 PET imaging agent. The goal is to assess the agent's ability to cross the human blood-brain barrier and validate its activation by myeloperoxidase (MPO) in the brains of patients with early-stage Alzheimer's disease. The award period runs from July 1, 2025 to June 30, 2026. This research aims to develop...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $455,009 to The General Hospital Corporation (doing business as Massachusetts General Hospital) to develop a novel [18F]-labeled amphiphilic PET probe that can cross the blood-brain barrier and track CD206+ microglia/macrophages in Alzheimer's disease. The goal is to create a non-invasive imaging method to detect anti-inflammatory M2-like microglia and macrophages, which play a key role in...